Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$65.13 +18.2%	$44.67	$30.04 ▼ $66.10	$4.76B	1.82	1.99 million shs	10.16 million shs
FATE Fate Therapeutics	$1.13 -1.7%	$1.21	$0.66 ▼ $5.92	$131.79M	2.18	2.17 million shs	972,860 shs
NBIX Neurocrine Biosciences	$132.02 -1.6%	$125.51	$84.23 ▼ $157.98	$13.27B	0.24	1.15 million shs	757,716 shs
VIR Vir Biotechnology	$5.41 -1.5%	$5.13	$4.32 ▼ $14.45	$758.93M	1.22	1.37 million shs	2.07 million shs
XLRN Acceleron Pharma	$178.75	$176.25	$108.82 ▼ $189.99	$10.93B	0.13	572,759 shs	N/A

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	-0.09%	-6.63%	+27.55%	+45.86%	-8.91%
FATE Fate Therapeutics	+1.77%	-0.86%	-4.17%	+3.60%	-74.22%
NBIX Neurocrine Biosciences	+0.47%	-0.60%	+7.39%	+32.28%	-7.29%
VIR Vir Biotechnology	+1.48%	-7.42%	+7.65%	-0.18%	-46.54%
XLRN Acceleron Pharma	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRSP CRISPR Therapeutics	2.69 of 5 stars	3.3	1.0	0.0	0.0	3.3	3.3	0.6
FATE Fate Therapeutics	3.6619 of 5 stars	3.1	1.0	0.0	4.7	1.9	1.7	0.6
NBIX Neurocrine Biosciences	4.4801 of 5 stars	3.4	3.0	0.0	2.9	2.4	2.5	1.9
VIR Vir Biotechnology	3.5865 of 5 stars	3.4	4.0	0.0	0.0	2.0	3.3	1.3
XLRN Acceleron Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRSP CRISPR Therapeutics	2.53	Moderate Buy	$71.75	10.16% Upside
FATE Fate Therapeutics	2.13	Hold	$3.83	239.23% Upside
NBIX Neurocrine Biosciences	2.87	Moderate Buy	$163.91	24.15% Upside
VIR Vir Biotechnology	2.88	Moderate Buy	$30.25	459.15% Upside
XLRN Acceleron Pharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CRSP, NBIX, XLRN, VIR, and FATE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
7/11/2025	VIR Vir Biotechnology	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy	$12.00
7/10/2025	NBIX Neurocrine Biosciences	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$182.00
7/9/2025	NBIX Neurocrine Biosciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$152.00 ➝ $174.00
7/8/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/27/2025	CRSP CRISPR Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00
6/27/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00
6/27/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00
6/26/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/26/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRSP CRISPR Therapeutics	$37.31M	150.75	N/A	N/A	$22.64 per share	2.88
FATE Fate Therapeutics	$13.63M	9.50	N/A	N/A	$2.80 per share	0.40
NBIX Neurocrine Biosciences	$2.36B	5.55	$3.33 per share	39.68	$25.58 per share	5.16
VIR Vir Biotechnology	$74.21M	10.08	N/A	N/A	$8.35 per share	0.65
XLRN Acceleron Pharma	$92.52M	118.15	N/A	N/A	$11.74 per share	15.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRSP CRISPR Therapeutics	-$366.25M	-$4.52	N/A	N/A	N/A	-1,023.64%	-20.08%	-17.13%	8/4/2025 (Estimated)
FATE Fate Therapeutics	-$186.26M	-$1.49	N/A	N/A	N/A	-1,318.93%	-47.17%	-34.60%	8/12/2025 (Estimated)
NBIX Neurocrine Biosciences	$341.30M	$2.95	44.75	20.40	1.37	12.68%	11.81%	8.59%	7/30/2025 (Estimated)
VIR Vir Biotechnology	-$521.96M	-$4.22	0.00	N/A	N/A	-2,769.04%	-47.46%	-39.33%	7/30/2025 (Estimated)
XLRN Acceleron Pharma	-$166.03M	-$4.21	N/A	N/A	N/A	-226.01%	-32.11%	-29.45%	N/A

Latest CRSP, NBIX, XLRN, VIR, and FATE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	FATE Fate Therapeutics	-$0.34	N/A	N/A	N/A	$1.16 million	N/A
8/7/2025	Q2 2025	VIR Vir Biotechnology	-$0.83	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.54	N/A	N/A	N/A	$6.44 million	N/A
7/30/2025	Q2 2025	NBIX Neurocrine Biosciences	$0.97	N/A	N/A	N/A	$653.09 million	N/A
5/13/2025	Q1 2025	FATE Fate Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	$1.18 million	$1.63 million
5/7/2025	Q1 2025	VIR Vir Biotechnology	-$0.83	-$0.88	-$0.05	-$0.88	$8.59 million	$3.03 million
5/6/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.27	-$1.58	-$0.31	-$1.58	N/A	N/A
5/5/2025	Q1 2025	NBIX Neurocrine Biosciences	$0.70	$0.08	-$0.62	$0.08	$587.06 million	$572.60 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A
XLRN Acceleron Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRSP CRISPR Therapeutics	N/A	15.64	15.64
FATE Fate Therapeutics	N/A	8.81	8.81
NBIX Neurocrine Biosciences	N/A	3.13	3.02
VIR Vir Biotechnology	N/A	6.79	6.79
XLRN Acceleron Pharma	N/A	12.14	12.14

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRSP CRISPR Therapeutics	69.20%
FATE Fate Therapeutics	97.54%
NBIX Neurocrine Biosciences	92.59%
VIR Vir Biotechnology	65.32%
XLRN Acceleron Pharma	90.35%

Insider Ownership

Company	Insider Ownership
CRSP CRISPR Therapeutics	4.30%
FATE Fate Therapeutics	5.51%
NBIX Neurocrine Biosciences	4.80%
VIR Vir Biotechnology	16.00%
XLRN Acceleron Pharma	1.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRSP CRISPR Therapeutics	460	86.36 million	82.65 million	Optionable
FATE Fate Therapeutics	550	114.60 million	108.29 million	Optionable
NBIX Neurocrine Biosciences	1,800	98.97 million	94.22 million	Optionable
VIR Vir Biotechnology	580	138.24 million	116.12 million	Optionable
XLRN Acceleron Pharma	312	61.16 million	60.12 million	Optionable

CRSP, NBIX, XLRN, VIR, and FATE Headlines

Recent News About These Companies

Acceleron P Stock Price Today | NASDAQ: XLRN Live - Investing.com

June 28, 2025 | investing.com

UK Approves Merck's Hypertension Drug Acquired Via $11 Billion Acceleron Pharma Deal

January 2, 2025 | benzinga.com

Acceleron advances cold fusion technology

December 17, 2024 | neimagazine.comN

Acceleron Banks on Muons for Colder Fusion

December 6, 2024 | msn.com

Merck preps filings after blockbuster-in-waiting Winrevair succeeds in severe PAH study

November 26, 2024 | fiercepharma.comF

Acceleron attracts turbocharged demand for debut Swissie

October 17, 2024 | globalcapital.comG

Acceleron Fusion has raised $15M to take a stab at colder fusion, filing reveals

October 5, 2024 | techcrunch.comT

Acceleron Fusion has raised $15M to take another stab at cold fusion, filing reveals

October 1, 2024 | yahoo.com

Merck confirms $11.5bn Acceleron takeover deal

August 6, 2024 | pharmaphorum.comP

Earnings to Watch Next Week: ON Semiconductor, Ferrari, General Motors and Moderna in Focus

April 26, 2024 | fxempire.comF

Big Pharma Q1 earnings roundup: AstraZeneca, BMS, Merck, Sanofi

April 26, 2024 | mmm-online.comM

ORBIMED CAPITAL GP II LLC's Net Worth

February 27, 2024 | benzinga.com

XLRN Historical Data

October 20, 2023 | investing.com

MSD eyes March FDA decision on PAH drug sotatercept

October 15, 2023 | pharmaphorum.comP

Brexit Bargain Buys: 14 More Stocks Picked by Morgan Stanley

April 15, 2023 | thestreet.com

Astellas Pharma Inc

March 17, 2023 | reuters.com

HempStreet partners with MGC Pharma launches ArtemiC

January 30, 2023 | health.economictimes.indiatimes.com

Acceleron Corp Becomes a Digital Correspondent Bank

December 14, 2022 | finance.yahoo.com

Pharma Contract Sales Market Report 2022-2032

November 30, 2022 | finance.yahoo.com

Merck to buy Imago for $1.35 bln to broaden portfolio of blood disorder drugs

November 21, 2022 | reuters.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
By Leo Miller | July 16, 2025
View 3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and Why
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
By Chris Markoch | June 29, 2025
View 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
1999 Again? The Danger of These 3 Companies Making Bitcoin Bets
By Gabriel Osorio-Mazilli | July 8, 2025
View 1999 Again? The Danger of These 3 Companies Making Bitcoin Bets
Whiplash for Investors: AeroVironment's Confusing Stock Signals
By Jeffrey Neal Johnson | July 2, 2025
View Whiplash for Investors: AeroVironment's Confusing Stock Signals
AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed
By Thomas Hughes | June 25, 2025
View AeroVironment Will Hit New Highs This Year: Bull Flag Confirmed

CRSP, NBIX, XLRN, VIR, and FATE Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

$65.13 +10.04 (+18.22%)

Closing price 04:00 PM Eastern

Extended Trading

$64.90 -0.23 (-0.35%)

As of 07:59 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Fate Therapeutics NASDAQ:FATE

$1.13 -0.02 (-1.74%)

Closing price 04:00 PM Eastern

Extended Trading

$1.18 +0.05 (+4.34%)

As of 07:55 PM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Neurocrine Biosciences NASDAQ:NBIX

$132.02 -2.09 (-1.56%)

Closing price 04:00 PM Eastern

Extended Trading

$131.99 -0.03 (-0.03%)

As of 05:19 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Vir Biotechnology NASDAQ:VIR

$5.41 -0.08 (-1.46%)

Closing price 04:00 PM Eastern

Extended Trading

$5.41 0.00 (0.00%)

As of 06:39 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Acceleron Pharma NASDAQ:XLRN

Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time